Document Detail


Vitamin E serum levels and controlled supplementation and risk of amyotrophic lateral sclerosis.
MedLine Citation:
PMID:  23286756     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
There are no observational studies or controlled trials of amyotrophic lateral sclerosis (ALS) and circulating α-tocopherol (vitamin E) for prevention of ALS. This study addresses that gap. The study population comprised 29,127 Finnish male smokers, aged 50-69 years, who participated in the Alpha-Tocopherol, Beta-Carotene Cancer Prevention (ATBC) Study, which is both a prospective cohort and a randomized, double-blind, placebo-controlled trial of α-tocopherol (50 mg/day) and β-carotene (20 mg/day). Serum α-tocopherol and β-carotene was assayed at baseline (1985 - 1988). Follow-up (median 16.7 years) continued through 2004. ALS cases were identified through the national Hospital Discharge Register with diagnostic verification by hospital records and death certificates. During 407,260 person-years of follow-up, 50 men were identified with ALS. For males with serum α-tocopherol concentration above the median (≥ 11.6 mg/l), the age-adjusted relative risk (RR) compared to α-tocopherol below the median, was 0.56 (95% confidence interval 0.32 - 0.99), p = 0.046. The RR among α-tocopherol supplement recipients was 0.75 (95% CI 0.32 - 1.79), p = 0.52. Neither serum β-carotene level nor β-carotene supplementation was associated with ALS. In conclusion, the results are consistent with a hypothesized protective effect of α-tocopherol on ALS risk. However, pooled analyses of cohorts with serum and controlled trials are needed to clarify the role of α-tocopherol in ALS risk.
Authors:
D Michal Freedman; Ralph W Kuncl; Stephanie J Weinstein; Nea Malila; Jarmo Virtamo; Demetrius Albanes
Related Documents :
19017696 - Degreasing and risk of non-hodgkin lymphoma.
17291406 - The immune response of women with prolonged exposure to electromagnetic fields produced...
4005386 - Case-control methods in the presence of multiple failure times and competing risks.
15786516 - Antipsychotic exposure and type 2 diabetes among patients with schizophrenia: a matched...
12482106 - Compliance with estrogen replacement therapy: current issues.
16423606 - Quality of life after growth hormone therapy and induced puberty in women with turner s...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2013-1-4
Journal Detail:
Title:  Amyotrophic lateral sclerosis and frontotemporal degeneration     Volume:  -     ISSN:  2167-9223     ISO Abbreviation:  Amyotroph Lateral Scler Frontotemporal Degener     Publication Date:  2013 Jan 
Date Detail:
Created Date:  2013-1-4     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101587185     Medline TA:  Amyotroph Lateral Scler Frontotemporal Degener     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Affiliation:
National Cancer Institute, Division of Cancer Epidemiology and Genetics , NIH, DHHS, Bethesda , Maryland.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Gastrostomy tube placement by endoscopy versus radiologic methods in patients with ALS: A retrospect...
Next Document:  Is exposure to cyanobacteria an environmental risk factor for amyotrophic lateral sclerosis and othe...